Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MIT...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Cell
Päätekijät: Smith, Michael P., Brunton, Holly, Rowling, Emily J., Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L., Girotti, Maria R., Marais, Richard, Levesque, Mitchell P., Dummer, Reinhard, Frederick, Dennie T., Flaherty, Keith T., Cooper, Zachary A., Wargo, Jennifer A., Wellbrock, Claudia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Cell Press 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4796027/
https://ncbi.nlm.nih.gov/pubmed/26977879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.02.003
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia